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Abstract
Background: In the hypothesis that the increased collagen metabolism in the intestinal wall of
patients affected by inflammatory bowel disease (IBD) is reflected in the systemic circulation, we
aimed the study to evaluate serum level of procollagen III peptide (PIIIP) in peripheral and
splanchnic circulation by a commercial radioimmunoassay of patients with different histories of
disease.
Methods: Twenty-seven patients, 17 with Crohn and 10 with ulcerative colitis submitted to
surgery were studied. Blood samples were obtained before surgery from a peripheral vein and
during surgery from the mesenteric vein draining the affected intestinal segment. Fifteen healthy
age and sex matched subjects were studied to determine normal range for peripheral PIIIP.
Results: In IBD patients peripheral PIIIP level was significantly higher if compared with controls
(5.0 ± 1.9 vs 2.7 ± 0.7 µg/l; p = 0.0001); splanchnic PIIIP level was 5.5 ± 2.6 µg/l showing a positive
gradient between splanchnic and peripheral concentrations of PIIIP. No significant differences
between groups nor correlations with patients' age and duration of disease were found.
Conclusions: We provide evidence that the increased local collagen metabolism in active IBD is
reflected also in the systemic circulation irrespective of the history of the disease, suggesting that
PIIIP should be considered more appropiately as a marker of the activity phases of IBD.
Background
Crohn's disease (CD) and Ulcerative Colitis (UC) are
chronic inflammatory bowel diseases (IBD) of unknown
origin of adolescent and young adulthood [1] where
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pathways activation [4], and environmental influences [5]
seem to concur at different levels in the pathogenesis and
the progression of IBD. These pathologic conditions are
characterized by focal or diffuse inflammation of the ali-
mentary tract, mucosal damage and epithelial destruction.
IBD may be associated with an inability of the intestinal
mucosa to protect itself from luminal challenges and
inappropriate repair following intestinal injury [6-10].
CD differs from UC by the transmural granulomatous
inflammation generally leading to fibrosis, strictures and
fistulas [11].
Current opinions suggest that an increased synthesis of
collagen type I, III, and V may play an important role in
the pathophysiological mechanism leading to intestinal
fibrosis [12-15]. An increased synthesis of collagen,
namely an increased of procollagen type III, is well docu-
mented in fibrotic processes involving other organs such
as liver, pancreas, and lung [16-18].
However, not all authors are in agreement regarding the
increased serum levels of the aminoterminal propeptide
(PIIIP) of collagen in peripheral and splanchnic circula-
tion of patients with active IBD [13,14]. Below we present
the results on the serum level of PIIIP in splanchnic and
peripheral circulation in patients with active IBD submit-
ted to surgery.
Methods
Twenty-seven patients affected by active IBD, 17 with CD
(age 40.2 ± 13.1, yrs from diagnosis 9.2 ± 5.5), and 10
with UC (age 50.3 ± 15.6, yrs from diagnosis 9.8 ± 7.4)
submitted to surgery, were enrolled in the study in a dou-
ble blind fashion. The protocol was approved by local
Ethical Committee and informed consent was obtained
from all participants to the study. Three patients had CD
in small bowel only, two in large bowel only, 12 had ile-
ocolonic disease. Disease activity was assessed according
to the Crohn's Disease Activity Index (CDAI) [19] and the
Truelove-Witts index (TWI) [20] for CD and UC, respec-
tively. According to CDAI, 2 patients were subclassified as
having a moderate form of disease while 15 patients were
subclassified as having a severe form of disease. According
to TWI, 3 patients were classified as having moderate form
of disease, 4 a mild form, and 3 a severe form of disease.
Patients affected by CD were operated on for recurrent
obstruction, whereas patients with UC were submitted to
surgery because of refractory to medical therapy.
The clinical diagnosis was confirmed by histology (Fig. 1);
all cases under study fulfilled the histological criteria as
follows:
Histological images obtained from two IBD patients enrolled in the study affected by CD (panel a) and UC (panel b) with 12.0 and 10.3 µg/l splanchnic levels f PIIIP, respectivelyFigure 1
Histological images obtained from two IBD patients enrolled in the study affected by CD (panel a) and UC (panel b) with 12.0 
and 10.3 µg/l splanchnic levels of PIIIP, respectively. Panel a, CD: in the transmural section is clearly evident an ulceration (o) in 
the mucosa and submucosa with diffuse inflammatory infiltrations, pseudo-follicle nodules (arrow), and fibrosis of the intestinal 
wall. Panel b, UC: the inflammatory infiltration is more evident in the mucosa and submucosa with criptic abscesses (asterisks). 
A serpiginous linear ulcer is evident (arrow).Page 2 of 6
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phoid nodules involving all layers of intestinal wall some-
time with sarcoid-type granulomas and serosal
inflammation;
- for UC: mucosal erosions and superficial ulcerations
usually limited to the upper submucosa with cryptic
abscesses and glandular destruction.
The clinical profile of the studied patients is reported
(Table 1). Two patients did not receive any medication,
whereas other patients received two or three drugs for the
treatment of IBD. Table 2 shows the treatment protocol
for all the studied patients. A control group of 15 healthy
age and gender matched subjects was also studied to
determine normal range for peripheral PIIIP.
Collagen metabolism (PIIIP)
Different kinds of collagen have been identified in
humans. All of them derive from longer precursor mole-
cules (procollagens). They are synthesized intracellularly
and secreted in extracellular space where they are cleaved
by aminoproteases [21-23]. Among the different kinds of
precursors, type III is one of the most abundant interstitial
procollagens. Since its aminoterminal propeptide, PIIIP,
is formed in equimolar proportions to collagen, serum
measurements of this fragment can provide an index of
collagen synthesis [23]. The blood samples (two, 5-ml
each) for PIIIP measurements were taken from the
median cubital vein (p-PIIIP) before surgery after an over-
night fast, during surgery from a mesenteric vein (s-PIIIP)
draining the intestinal segment chosen for resection by
the surgeon. Serum levels of PIIIP were assessed by com-
mercial radioimmunoassay (Orion Diagnostics, Finland).
The intra-assay and inter-assay variation were respectively
4% and 4.3%, mean 2.6 µg/l. Normal ranges of peripheral
PIIIP concentrations assessed in the control group were
2.7 ± 0.7 µg/l.
Statistical analysis
Data were analyzed using a computer statistical software
(SPSS-Rel 10; SPSS Inc., Chicago, Ill). All the quantitative
variables were tested for Gaussian distribution with the
Kolmogorov-Smirnov test. All that followed this distribu-
tion were presented as mean ± standard deviation.
Differences at baseline in collagen parameters between
IBD patients and controls were tested for significance
using the analysis of variance with the Bonferroni correc-
tion. The relation between collagen parameters and the
estimated duration of the disease and indices of disease
were tested with regression analysis. In all cases, a p value
less than 0.05 was considered significant.
Results
Peripheral PIIIP assay
At baseline, before surgery, serum p-PIIIP in IBD patients
were significantly higher if compared with healthy con-
trols (5.0 ± 1.9 vs 2.7 ± 0.7 µg/l, respectively; p = 0.0001)
(fig 2a). No significant differences were found when com-
paring CD and UC subgroups (5.0 ± 1.6 vs 4.9 ± 2.4 µg/l,
respectively; p = ns) (fig 2b).
Table 1: Clinical aspects of the studied patients
Disease N° of 
patients
Age Sex Years from 
diagnosis
Activity 
index
Crohn CDAI
1 34 F 12 Severe
2 35 M 8 Moderate
3 38 M 15 Severe
4 32 F 8 Severe
5 43 F 14 Severe
6 35 M 8 Severe
7 58 M 5 Severe
8 61 F 7 Severe
9 33 M 8 Severe
10 35 F 19 Severe
11 21 F 4 Severe
12 72 F 1 Severe
13 36 M 15 Moderate
14 42 M 7 Severe
15 25 F 6 Severe
16 51 F 18 Severe
17 34 M 1 Severe
Ulcerative 
colitis
TWI
1 68 F 15 Severe
2 70 F 1 Moderate
3 21 F 3 Mild
4 54 F 20 Moderate
5 52 M 20 Mild
6 38 M 4 Moderate
7 64 M 6 Mild
8 38 F 16 Severe
9 41 F 3 Severe
10 57 M 10 Mild
CDAI: Crohn's Disease Activity Index; TWI: truelove-Witts index.
Table 2: Frequency distribution for therapy
Therapy N° of 
patients
Crohn Ulcerative 
colitis
No 2 1 1
Aminosalicydic acid 9 8 1
Cortisone 2 2 0
Aminosalicydic acid + Cortisone 14 6 8
Total 27 17 10Page 3 of 6
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During surgery, serum s-PIIIP in IBD patients was 5.5 ±
2.6 µg/l. No significant differences were found when com-
paring CD and UC subgroups (5.4 ± 2.3 vs 5.7 ± 3.1 µg/l,
respectively; p = ns). A positive gradient was found in IBD
patients between splanchnic and peripheral serum con-
centrations of PIIIP (0.7 ± 1.9 µg/l). This gradient was
confirmed when separately considering each disease,
without significant differences between the two sub-
groups (CD 0.3 ± 1.3 vs UC 1.3 ± 2.6 µg/l; p = ns) (fig 2c).
Other variables and PIIIP levels
No significant correlation was found between peripheral
and splanchnic levels of PIIIP and the age of the patients
and the estimated duration of the disease. Regarding the
activity indices, the number of patients belonging to each
class was not enough to perform a statistical analysis. Not-
withstanding, for the TWI in UC patients a significant dif-
ference in PIIIP levels was found between mild and severe
form of the disease (Table 3). Finally, no significant differ-
ences were found in PIIIP levels between patients treated
with glucocorticoids compared with patients not receiving
this treatment.
Discussion
CD and UC are chronic pathologies characterized by an
early onset followed by sporadic episodes of acute symp-
toms during lifetime, debilitating the affected patients to
perform their daily functions [24]. Until now controver-
sial theories exist about the synthesis and degradation of
PIIIP, its level on systemic circulation, and its deposition
far for main target organ [12,13,15,25].
In the present study we have found that intestinal collagen
metabolism in IBD patients was increased and that it is
reflected in local and systemic circulation. Differently
from some experiences [12,13], we have found that serum
PIIIP levels in IBD patients was significantly higher if
Panel a: Differences in baseline p-PIIIP values in Controls and IBD patientsFigure 2
Panel a: Differences in baseline p-PIIIP values in Controls and IBD patients. Panel b: No significant differences in p-PIIIP values 
between CD and UC subgroups. Panel c: Differences between splancnic and periferic values of PIIIP, without significant differ-
ences in CD and UC sbgroups. p-PIIIP: periferic (median cubital vein) PIIIP; s-PIIIP: splancnic (mesenteric vein) PIIIP; ∆-PIIIP: dif-
ferences between s- and p-PIIIP in IBD patients; IBD: inflammatory bowel diseases; CD: Crohn's Disease; UC: ulcerative colitis;
Table 3: Baseline p-PIIIP levels in UC patients
TWI Activity Index Mean ± SD
Mild 7.05 ± 2.25
Moderate 3.9 ± 1.11
Severe 3.13 ± 1.57*
* p = 0.02 vs mildPage 4 of 6
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ences were found in peripheral and splanchnic circulation
between patients affected by UC and CD. We also found a
positive gradient between serum s-PIIIP and p-PIIIP levels
in IBD patients. This gradient was confirmed when con-
sidering serum s-PIIIP and p-PIIIP in UC and CD sepa-
rately, even if the differences between the two subgroups
were not statistically significant. In our experience no sig-
nificant differences were found when considering the age
of the patients, the duration of the disease, and the activity
indices. This fact implies that serum PIIIP should not be
considered a long-term marker of the disease, probably
reflecting the short-term fluctuation in the activity phases
of the remodeling processes.
When comparing the mild with the severe form of the dis-
ease, a significant difference in PIIIP levels was found only
in patients affected by UC. This data will probably be con-
firmed when the number of patients enrolled in each dis-
ease-related activity categories is extended as presently in
our series the majority of the patients were classified as
severe.
The effect of glucocorticoids on collagen synthesis, colla-
genase, and collagen degradation has not yet fully been
clarified [25]. In our study the cortisone therapy did not
have influence on the PIIIP levels, but the number of
patients was too small and it was not possible to speculate
on this regard.
Conclusions
In conclusion we provide evidence that collagen metabo-
lism in IBD is reflected in the systemic and local circula-
tion, without any differences between UC and CD,
irrespective of the age of the patients and the duration of
the disease. Therefore, this marker may give further infor-
mation on the activity phases rather than on the entire
history of the disease. Further data on the possible use of
PIIIP as useful marker of choice for surgical option are
attended from the follow-up at 6 and 12 months, which is
still on-going [26].
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